Satellite Symposia

Satellite symposia are non-commercial, grant funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2023. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

Registration, content, and continuing education is the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.

Tuesday, Oct. 11, 2022| 2–4pm  

Managed Care and Population Health Considerations in Modern Pneumococcal Vaccination: Moving the Needle on Infectious Outcomes

 

  • Provider Med Learning Group 
  • Supported by This activity is supported by an educational grant from Merck & Co., Inc. 
  • Continuing education credit available for this activity is designed to meet the educational needs of managed care practitioners as well as primary care physicians, nurse practitioners, pharmacists, and other members of the multidisciplinary team who evaluate patients for vaccination needs 
  • Contact hours: 1.0 

Program Description 

This interactive, case-based program will explore the risk of pneumococcal infections from a population perspective. Through didactic discussion and case-based learning, this program aims to engage pharmacists and other health care professionals in understanding the importance and timing of pneumococcal vaccination, as well as the managed care implications. 

Learning Objectives 

  • Evaluate the risk of pneumococcal infection from a population perspective and consider the importance of various serotypes in managed care considerations 
  • Assess clinical data and specific data with pneumococcal serotypes to contextualize treatment options in the context of guidelines 
  • Apply best practices for managed care in implementing pneumococcal vaccination schedules to improve health outcomes for members 

Program Manager 

Felecia Beachum 
Med Learning Group 
fbeachum@medlearninggroup.com 

Registration Link:  

www.MLG-AMCP.com 

Tuesday, Oct. 11, 2022| 6–7:30pm

Evolving Management Options for Alopecia Areata: Clinical Burden, Cost Effective Care, and Emerging Treatments

 

  • This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc. This CE activity for ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc. 
  • This activity is supported by an educational grant from Pfizer, Inc. 
  • This educational activity has been designed for community pharmacists, specialty pharmacists, and healthcare professionals in allergy, immunology, dermatology and managed care who manage patients with AA. 
  • Contact hours: 1.5 

Program Description 

The hair loss that occurs in patients with alopecia areata (AA) imposes a significant psychological burden on the over 300,000 US individuals affected by the disease each year. Traditionally, AA management has been limited to the off-label use of various treatments, many of which can be associated with significant side effects and often provide only limited relief. As understanding of AA pathophysiology has evolved, we have witnessed the development of a number of novel targeted therapies. Foremost among these are multiple JAK inhibitors, one of which has just been approved by the FDA. Join our esteemed clinician faculty for a review of the recently approved and emerging JAK inhibitor therapies for AA. Complemented with case-based learning and faculty roundtable discussions, this symposium is designed to help clinicians achieve better outcomes for their patients with AA.  

Learning Objectives 

  • Outline the pathophysiology and clinical burden of alopecia areata (AA) 
  • Recall clinical data on emerging agents for AA to determine their potential placement in the treatment landscape 
  • Describe strategies for reimbursement and navigating cost issues associated with emerging AA therapies 

Program Manager 

NyQwayah Brown 
Integrity Continuing Education, Inc. 
nbrown@integrityce.com 

Registration Link: 

 https://integrityce.com/Nexus2022  

Wednesday, Oct. 12, 2022| 6–8pm (National Harbor 2/3) 

Optimizing Solid Tumor Management with PARP Inhibition STRATEGIES FOR A CHANGING PARADIGM 
  • Provider Creative Educational Concepts, LLC 
  • Supported by AstraZeneca and Merck 
  • Continuing education credit available for oncology, specialty, and managed care pharmacists and physicians attending the 2022 Academy of Managed Care Pharmacy (AMCP) Nexus Annual Meeting 
  • Contact hours: 1.5 

Program Description 

Activity attendees will gain an understanding of the role of the DNA damage response (DDR) pathway in solid tumor tumorigenesis and the latest guidelines and importance of genetic testing/counseling and related treatment recommendations; then they will be guided through an appraisal of current and emerging evidence for PARP inhibitors for solid tumor management. An expert-led discussion in transcending disparities in cancer care and improving equitable access will follow, as will a review of PARP inhibitor toxicity profiles and how to effectively anticipate, prevent, and manage adverse events that may arise. After the didactic portion of the presentation, an interactive case-based presentation will provide attendees an opportunity to apply what they have learned, with an emphasis on appropriate treatment selection, toxicity management, mitigation of modifiable health disparities, and promotion of patient adherence to oral oncolytic therapy. 

Learning Objectives 

  • Appraise current expert consensus guideline recommendations for managing solid tumor malignancies with PARP inhibitors, including evidence-based approaches for anticipating, mitigating, and managing adverse events. 
  • Evaluate the crucial importance of genetic testing/counseling when considering PARP inhibitor therapy for patients with solid tumors. 
  • Review emerging PARP inhibitor clinical trial data in both the treatment and maintenance settings for solid tumors and discuss how these agents continue to galvanize change across the disease management continuum 
  • Recognize healthcare disparities that result in inequitable access and identify approaches for overcoming these obstacles and improving outcomes for all patients. 
  • Use a case-based approach to develop practical strategies for appropriate treatment selection, toxicity management, mitigation of healthcare disparities and inequitable access to care, and promotion of patient adherence to PARP inhibitors and other oral oncolytics, with the express goal of improving outcomes across the solid tumor landscape. 

Program Manager 

Ashley Lilly, MPA 
Creative Educational Concepts, LLC 
lillya@ceconcepts.com 

Registration Link:  

https://www.ceconcepts.com/parp-2022 

Thursday, Oct. 13, 2022, 6–8pm

Iron Deficiency: Managed Care Considerations for Optimizing Evidence-Based and Cost-Effective Use of IV Iron Replacement Therapies

 

  • Provider ProCE 
  • Supported by American Regent 
  • This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with iron deficiency, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 
  • Contact hours: 1.5 

Program Description 

Iron deficiency is often associated with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD), and inflammatory bowel disease (IBD). This educational activity will review the role of IV iron replacement in iron deficiency and accompanying chronic conditions and focus on the economic burden of these diseases and the impact of IV iron on healthcare resource utilization. 

Learning Objectives 

  • Recognize the etiology, pathophysiology, and impact of iron deficiency in common comorbidities such as HF, CKD, and IBD 
  • Discuss efficacy and safety data regarding IV iron replacement therapies for the treatment of iron deficiency in concomitant chronic conditions, as well as recommended dosing and appropriate implementation of these agents 
  • Determine strategies to optimize access to appropriate patient-centered therapies and mitigate financial burdens to improve the management of iron deficiency and promote efficient healthcare resource utilization 

Program Manager 

Cara Blair 
ProCE 
cblair@clinicaloptions.com 

Registration Link:

https://bit.ly/3di2SaK 

For more information, please contact us.